Kiadis Pharma NV (KDS):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Kiadis Pharma NV (KDS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7997
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:38
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オランダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Kiadis Pharma NV (Kiadis) is a biopharmaceutical company that develops and markets cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. The company offers cellular products including ATIR101 and ATIR201 for infusion. Its ATIR101 lowers the risks and limitations in blood cancers, cancer relapse, opportunistic infections, and limited donor availability. Kiadis develops ATIR201 for the treatment of thalassemia. Its product candidates are produced using the proprietary TH9402 compound which selectively targets and depletes rapidly dividing cells such as immune reactive cells in a mixed lymphocyte reaction between donor and patient material. The company uses theralux platform to develop therapeutic products. Its products serve the needs of patients suffering from hematological malignancies and blood cancer transplant. Kiadis is headquartered in Amsterdam, the Netherlands.

Kiadis Pharma NV (KDS) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Kiadis Pharma NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Kiadis Pharma NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Kiadis Pharma NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Kiadis Pharma NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Kiadis Pharma NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Kiadis Pharma NV, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Kiadis Pharma Raises US$12.8 Million In Financing Round 10
Partnerships 12
Kiadis Pharma Enters into Agreement with PCT 12
Kiadis Pharma Enters into Agreement with Thalassaemia International Federation 13
Equity Offering 14
Kiadis Pharma Raises USD36 Million in Private Placement of Shares 14
Kiadis Pharma Raises USD28.8 Million in Private Placement of Shares 16
Kiadis Pharma Raises USD5.6 Million in Private Placement of Shares 18
Kiadis Pharma Raises USD0.8 Million in Second Tranche of Private Placement of Shares 19
Kiadis Pharma Raises USD1 Million in Private Placement of Shares 20
Kiadis Pharma Completes IPO 21
Kiadis Pharma NV – Key Competitors 23
Kiadis Pharma NV – Key Employees 24
Kiadis Pharma NV – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 26
Financial Announcements 26
Aug 31, 2018: Kiadis Pharma announces financial results for the six months ended June 30, 2018 and company update 26
Apr 13, 2018: Kiadis Pharma Announces Annual Results For Year Ended December 31, 2017 27
Aug 25, 2017: Kiadis Pharma announces Financial Results for the six months ended June 30, 2017 28
Mar 31, 2017: Kiadis Pharma announces Annual Results for the year ended December 31, 2016 30
Corporate Communications 31
Sep 06, 2018: Kiadis Pharma announces two senior management appointments 31
Aug 30, 2018: Kiadis Pharma announces senior management changes 32
Jun 05, 2018: Kiadis Pharma announces results of Annual General Meeting 33
Jan 16, 2018: Kiadis Pharma proposes former Cipla CEO Subhanu Saxena as new Supervisory Board member 34
Sep 29, 2017: Kiadis Pharma appoints Dr. Andrew Sandler as Chief Medical Officer 35
Mar 20, 2017: Kiadis Pharma appoints Jan Feijen as Chief Operations Officer 36
Other Significant Developments 37
Feb 14, 2018: The Alliance for Regenerative Medicine Announces Initial Slate of Presenting Companies at the Sixth Annual Cell & Gene Therapy Investor Day 37
Appendix 38
Methodology 38
About GlobalData 38
Contact Us 38
Disclaimer 38

List of Tables
Kiadis Pharma NV, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Kiadis Pharma NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Kiadis Pharma NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Kiadis Pharma NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Kiadis Pharma NV, Deals By Therapy Area, 2012 to YTD 2018 8
Kiadis Pharma NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Kiadis Pharma Raises US$12.8 Million In Financing Round 10
Kiadis Pharma Enters into Agreement with PCT 12
Kiadis Pharma Enters into Agreement with Thalassaemia International Federation 13
Kiadis Pharma Raises USD36 Million in Private Placement of Shares 14
Kiadis Pharma Raises USD28.8 Million in Private Placement of Shares 16
Kiadis Pharma Raises USD5.6 Million in Private Placement of Shares 18
Kiadis Pharma Raises USD0.8 Million in Second Tranche of Private Placement of Shares 19
Kiadis Pharma Raises USD1 Million in Private Placement of Shares 20
Kiadis Pharma Completes IPO 21
Kiadis Pharma NV, Key Competitors 23
Kiadis Pharma NV, Key Employees 24
Kiadis Pharma NV, Subsidiaries 25

List of Figures
Kiadis Pharma NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Kiadis Pharma NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Kiadis Pharma NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Kiadis Pharma NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Kiadis Pharma NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Kiadis Pharma NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Kiadis Pharma NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Kiadis Pharma NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Kiadis Pharma NV (KDS):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Basware Oyj (BAS1V):企業の財務・戦略的SWOT分析
    Basware Oyj (BAS1V) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Global Bio-chem Technology Group Company Limited (809):企業の財務・戦略的SWOT分析
    Global Bio-chem Technology Group Company Limited (809) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s …
  • Department of Defense Education Activity:企業の戦略的SWOT分析
    Department of Defense Education Activity - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and …
  • Sanderson Farms Inc:戦略・SWOT・企業財務分析
    Sanderson Farms Inc - Strategy, SWOT and Corporate Finance Report Summary Sanderson Farms Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Myer Holdings Ltd:企業の戦略・SWOT・財務分析
    Myer Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Myer Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Nexif Energy Management Pte Ltd:電力:M&Aディール及び事業提携情報
    Summary Nexif Energy Management Pte Ltd (Nexif Energy) a subsidiary of Nexif Pte Ltd invests in power projects in partnership with Denham Capital. The company carries out the development and management of power and infrastructure projects in South Asia and South East Asia. It develops and manages po …
  • Pegasi Energy Resources Corp:石油・ガス:M&Aディール及び事業提携情報
    Summary Pegasi Energy Resources Corp (PERC) is an energy company that explores, produces, and develops oil and natural gas from its properties. The company produces natural gas and oil through the development of a low geological, repeatable, and high potential project in the Rodessa East Texas oil a …
  • CryoLife Inc (CRY):企業の財務・戦略的SWOT分析
    CryoLife Inc (CRY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Borges International Group SLU:企業の戦略的SWOT分析
    Borges International Group SLU - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • Gerdau S.A.:企業の戦略・SWOT・財務情報
    Gerdau S.A. - Strategy, SWOT and Corporate Finance Report Summary Gerdau S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Marston’s PLC:企業の戦略・SWOT・財務情報
    Marston's PLC - Strategy, SWOT and Corporate Finance Report Summary Marston's PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Mersana Therapeutics Inc (MRSN)-製薬・医療分野:企業M&A・提携分析
    Summary Mersana Therapeutics Inc (Mersana) formerly Nanopharma Corp, is a biotechnology company that develops immunoconjugate therapies to improve patients’ lives. The company offers pipeline product XMT-1522, for HER-2 targeted therapies based on its Dolaflexin platform. It utilizes its Fleximer an …
  • Plains All American Pipeline LP (PAA):企業の財務・戦略的SWOT分析
    Plains All American Pipeline LP (PAA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • Big Lots, Inc.:企業の戦略・SWOT・財務情報
    Big Lots, Inc. - Strategy, SWOT and Corporate Finance Report Summary Big Lots, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Towngas China Co Ltd (1083):石油・ガス:M&Aディール及び事業提携情報
    Summary Towngas China Co Ltd (Towngas China), a subsidiary of The Hong Kong and China Gas Co Ltd is an oil and gas company that distributes natural gas. The company's business activities include sale and distribution of pipeline gas, gas pipe network construction, operating urban pipeline gas networ …
  • Canara Bank (CANBK):企業の財務・戦略的SWOT分析
    Canara Bank (CANBK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Skanska AB (SKA B):企業の財務・戦略的SWOT分析
    Skanska AB (SKA B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • John Wiley & Sons, Inc.:企業のM&A・事業提携・投資動向
    John Wiley & Sons, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's John Wiley & Sons, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisition …
  • Eurofarma Laboratorios SA-製薬・医療分野:企業M&A・提携分析
    Summary Eurofarma Laboratorios SA (Eurofarma), formerly Bill Farmaceutica is a pharmaceutical company that manufactures and markets prescription, generic and veterinary drugs. The company offers prescription products which include aerosol ointment, alprazolam, acebrophylline, altiva, ebastel, fluoru …
  • NIH Office of Technology Transfer:製薬・医療:M&Aディール及び事業提携情報
    Summary NIH Office of Technology Transfer (NIH OTT), a subsidiary of National Institutes of Health is a healthcare service provider that evaluates, protects, markets, licenses, monitors, and manages NIH and FDA discoveries, inventions, and other intellectual property. The center discovers new biolog …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆